Zentiva

Zentiva is a Pan-European Platform that aims to make healthcare a right rather than a privilege. Since its founding in 2003, the company has been developing, manufacturing, and providing high-quality and affordable medicines to over 100 million people in Europe. Zentiva operates with 4 wholly owned manufacturing sites and a broad network of external manufacturing partners to ensure supply security. Its solutions focus on key therapeutical areas such as Cardiology & Circulation, Diabetes, Oncology, Respiratory, and CNS, with a strategic expansion into self-care. The company, headquartered in the Czech Republic, is overseen by Private Equity ownership and has been delivering sustainable double-digit growth. With an ambitious 5-year plan, Zentiva is set to pursue strong (organic and inorganic) growth across Europe. With nearly 5,000 unique talents working towards the common goal of providing access to high-quality and affordable medicines, Zentiva aims to create a welcoming and appreciative work environment where everyone can contribute to the best of their abilities. Currently, there is no available information regarding the last investment or the last investment's investors. However, with its clear mission and strong performance, Zentiva presents itself as a compelling opportunity for potential investors looking to make a meaningful impact in the healthcare, manufacturing, and pharmaceutical industries.